A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group
Children's Oncology Group
Astellas Pharma Inc
Delta-Fly Pharma, Inc.
Astellas Pharma Inc
National Cancer Institute (NCI)
Children's Oncology Group
Technische Universität Dresden
Cornerstone Pharmaceuticals
SWOG Cancer Research Network
Children's Oncology Group
University of Birmingham
University of Ulm
Polish Adult Leukemia Group
Children's Oncology Group
M.D. Anderson Cancer Center
Canadian Cancer Trials Group
Pfizer
M.D. Anderson Cancer Center
Exelixis
Pfizer
Ludwig-Maximilians - University of Munich
University of Ulm
German CLL Study Group
Memorial Sloan Kettering Cancer Center
SWOG Cancer Research Network
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
GOG Foundation
St. Jude Children's Research Hospital
European Organisation for Research and Treatment of Cancer - EORTC
Pfizer
Sanofi
European Organisation for Research and Treatment of Cancer - EORTC
Swiss Cancer Institute
Fondazione Italiana Linfomi - ETS
National Cancer Institute (NCI)
Acute Leukemia French Association